[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Colorado, Denver\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":662},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,270,0,25,[9,44,77,107,131,156,177,202,228,256,283,314,343,366,393,412,436,460,483,506,536,565,592,619,641],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100652806","phase-2-precision-medicine-adaptive-network-platform-trial-in-hypoxemic-acute-respiratory-failure-100652806",false,"NCT07779642","Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure","US-PANTHER","Inclusion Criteria:\n\nCritically ill patients in hospital and at least 1 of the following:\n\n1. Acute respiratory distress syndrome (ARDS). ARDS as defined by:\n\n   1. a known acute clinical insult or new or worsening respiratory dysfunction\n   2. receiving respiratory support via invasive mechanical ventilation or non- invasive mechanical ventilation including continuous positive airway pressure, or high flow nasal oxygen greater than or equal to 30L\u002Fmin\n   3. within the same 24-hour time period:\n\n   i. bilateral opacities on chest imaging not fully explained by effusion, lobar\u002Flung collapse\u002Fatelectasis, or nodules ii. respiratory failure not fully explained by cardiac failure, fluid overload, pulmonary embolism, acute airway disease iii. Pa02\u002FFi02 ration \\\u003C40 kPa from arterial blood gases, or Sp02 \\\u003C315 from pulse oximetry where Sp02 \\\u003C97\n2. A pandemic associated syndrome\n\nExclusion criteria:\n\nSimvastatin:\n\n1. More than 48 hours from the diagnosis of AHRF\n2. Patient is known to be pregnant\n3. Liver transaminases \\>8 times the upper limit of the normal range\n4. Creatine kinase \\>10 times the upper limit of the normal range\n5. Currently receiving ongoing treatment with any of the following: itraconazole, ketoconazole, HIV protease inhibitors, nefazodone, cyclosporine, amiodarone, verapamil, or diltiazem.\n6. Severe renal impairment (eGFR \\\u003C 30mL\u002Fmin and not receiving renal replacement therapy).\n7. Current or recent treatment (within 2 weeks) with statins\n8. Physician decision that a statin is required for proven indication\n9. Contraindication to enteral drug administration, e.g., patients with mechanical bowel obstruction. Patients with high gastric aspirates due to an ileus are not excluded.\n10. Known hypersensitivity to simvastatin\n\nBaricitinib\n\n1. More than 48 hours from the diagnosis of AHRF\n2. Patient is known to be pregnant\n3. Liver transaminases \\>8 times the upper limit of the normal range\n4. Absolute neutrophil count less than 0.5x10 9\u002FL\n5. Currently receiving ongoing immunosuppressants (high dose corticosteroids, B and T cell targeted therapies, interferon, or JAK inhibitors)\n6. Severe renal impairment (eGFR \\\u003C 15mL\u002Fmin) or receiving renal replacement therapy\n7. Known active tuberculosis infection or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines.\n8. Contraindication to enteral drug administration, e.g., patients with mechanical bowel obstruction. Patients with high gastric aspirates due to an ileus are not excluded.\n9. Known hypersensitivity to baricitinib","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this trial is to accelerate the development of pharmacological therapies for critical illness by identifying biological subphenotypes in patients with acute respiratory distress syndrome (ARDS). The trial will stratify participants by biological markers into different subphenotypes, then randomized 1:1:1 to active treatment 1, active treatment 2, or usual care. Initial stratification will be into hyperinflammatory and hypoinflammatory subphenotypes in ARDS based on plasma biomarker profiles. Regular adaptive analyses will enable efficient identification of treatment effects within each subphenotype, stopping interventions where there is evidence of efficacy or futility, and bringing in new interventions and potentially new subphenotypes.",[27,28],"ARDS (Acute Respiratory Distress Syndrome)","Acute Hypoxic Respiratory Failure",[30,31],"ARDS","acute hypoxic respiratory failure","NOT_YET_RECRUITING","2026-08-18",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":21},"2026-09",{"date":40,"type":21},"2030-09",{"name":42,"class":43},"University of Colorado, Denver","OTHER",{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100354889","phase-1-losartan--sunitinib-in-treatment-of-osteosarcoma-100354889","NCT03900793","Losartan + Sunitinib in Treatment of Osteosarcoma","A Phase I\u002FIb Study of Losartan in Combination With Sunitinib in the Treatment of Pediatric and Adult Patients With Relapsed or Refractory Osteosarcoma","Inclusion Criteria:\n\n* 1\\. Provision to sign and date the consent form (if individual is a minor, provision of a parent or legal guardian to sign and date the consent form and provision of individual to provide assent for study).\n\n  2\\. Stated willingness to comply with all study procedures and be available for the duration of the study.\n\n  3\\. Male or female aged ≥ 10 years old. 4. Histologically confirmed osteosarcoma (at either original diagnosis or relapse) that has either recurred or progressed after at least one prior systemic therapy and for which no curative therapy exists.\n* Patients with surface or periosteal osteosarcoma are not eligible.\n* Patients with active CNS metastasis are not eligible. Previously treated CNS metastases which occurred 3 months or more prior, without evidence of active recurrence, are acceptable.\n\n  5\\. Disease status\n* Dose Escalation (Part A): Patients must have measurable or evaluable disease.\n* Cohort Expansion (Part B): Patients with measurable or evaluable disease and those with completely resected disease are eligible.\n\n  6\\. Performance status:\n* ECOG performance status (≥18 years old) ≤ 2 or Karnofsky performance score (\\\u003C18 years old)≥ 50.\n\n  7\\. Prior Therapy:\n* Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met (e.g., blood count criteria) the patient is considered to have recovered adequately.\n\n  1. Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive. At least 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea).\n  2. Anti-cancer agents not known to be myelosuppressive (e.g., not associated with reduced platelet or ANC counts): ≥ 7 days after the last dose of agent.\n\n  i. Antibodies: ≥ 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to Grade ≤ 1.\n\nii. Corticosteroids: ≥ 14 days must have elapsed since last dose of corticosteroid.\n\niii. Hematopoietic growth factors: ≥ 14 days after the last dose of a long- acting growth factor (e.g., pegfilgrastim) or 7 days for short-acting growth factor.\n\niv. Interleukins, Interferons and Cytokines (other than hematopoietic growth factors): ≥ 21 days after the completion of interleukins, interferon or cytokines (other than Hematopoietic Growth Factors).\n\nv. Stem cell Infusions: Autologous stem cell infusion, including boost infusion: ≥ 42 days.\n\nvi. Cellular Therapy: ≥ 42 days after the completion of any type of cellular therapy (e.g., modified T cells, NK cells, dendritic cells, etc.) vii. XRT\u002FExternal Beam Irradiation including protons: ≥ 14 days after local XRT; ≥ 150 days after TBI, craniospinal XRT or if radiation to ≥ 50% of the pelvis; ≥ 42 days if other substantial bone marrow radiation.\n\n* NOTE: Patients with history of cardiac irradiation with mean cardiac dose \\> 15 Gy are not eligible (see exclusion criteria).\n\n  8\\. Adequate bone marrow function, defined as:\n* Peripheral absolute neutrophil count (ANC) ≥ 750\u002Fmm3\n* Platelet count ≥ 75,000\u002Fmm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).\n* Hemoglobin ≥ 8 g\u002FdL (with or without transfusion) 9. Adequate renal function, defined as:\n* Creatinine clearance or radioisotope GFR \\> 70 mL\u002Fmin\u002F1.73 m2 OR a serum creatinine based on age\u002Fgender.\n\n  10\\. Adequate hepatic function, defined as:\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age\n* SGPT (ALT) ≤ 135 U\u002FL. For the purpose of this study, the ULN for SGPT is 45 U\u002FL.\n* Serum albumin ≥ 2.8 g\u002FdL 11. Patients with ≥ trace protein on urinalysis at screening will be allowed to enroll in the study at investigator discretion. A baseline urine protein creatinine ratio (UPC) should be obtained for patients with ≥ trace protein on urinalysis for consideration regarding Section 6.3.7 dose modification requirements.\n\n  12\\. Adequate cardiac function, defined as:\n* Current cardiac ejection fraction \\> 50% by biplane Simpson method on echocardiogram\n* QTc ≤ 480 ms 13. Patients with preexisting hyper- or hypothyroidism must be on a stable dose of medication.\n\n  14\\. Ability to take and retain oral medications. NOTE: Medication can be administered via nasogastric or gastrostomy tube.\n\nExclusion Criteria:\n\n1. Patients who underwent major surgery within 14 days prior to start of treatment are not eligible.\n\n   NOTE: Core biopsy or central line placement are considered minor and are allowed within any time limitations.\n2. Patients with uncontrolled coagulopathy or bleeding disorder, or any active bleeding (i.e., gastrointestinal or pulmonary) deemed to be clinically significant by investigator are not eligible.\n3. Patients with history of pulmonary embolism or significant thromboembolic event with the preceding 28 days. Patients with thromboembolic events \\> 28 days before enrollment who are stable on or completed an anticoagulation course are eligible.\n4. Patients with history of cardiac irradiation with mean cardiac dose \\> 15 Gy are not eligible.\n5. Patients with symptomatic cardiac disease (i.e. New York Heart Association or Modified Ross Heart Failure Classification for Children \\> class 2) are not eligible.\n6. Patients with any history of cardiac dysfunction including prior abnormal echocardiogram (ejection fraction \\\u003C 50%), severe or unstable angina, peripheral vascular disease, congenital prolonged QTc syndrome, clinically significant cardiac arrhythmias, stroke, or myocardial infarction are not eligible.\n7. Pregnancy\n\n   * Pregnant or breast-feeding women will not be entered on this study because there is not yet available information regarding human fetal or teratogenic toxicities. Pregnancy tests must be obtained in females who are post-menarchal.\n   * Males or females of reproductive potential may not participate unless they have agreed to practice 1 highly effective and 1 additional effective (barrier) method of contraception at the same time during the entire study treatment period and through 3 months after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. Patients who themselves or their partners have undergone female or male sterilization do not require 2 methods of contraception. Highly effective methods are defined as those with \\\u003C1% failure rate with perfect use and include: oral contraceptive pills (combined or progesterone only), intrauterine devices (IUD), hormonal implant or injection, contraceptive patch, and vaginal ring.\n8. Concomitant medications:\n\n   * Anti-hypertensives: Patients who cannot be controlled to goal blood pressure for gender\u002Fage are not eligible.\n   * Corticosteroids: Patients receiving systemic corticosteroids are not eligible. \\> 14 days must have elapsed since last systemic corticosteroid. Note: patients using topical or inhaled corticosteroids are eligible.\n   * Investigational Drugs: Patients currently receiving another investigational drug are not eligible.\n   * Anti-cancer agents: Patients currently receiving other anti-cancer agents are not eligible.\n   * Drug interactions: Patients who require treatment with medications that are strong inhibitors or inducers of CYP3A4 or inhibitors of CYP2A9 or have received these medications in the 7 days prior to enrollment, are not eligible. Patients who require treatment with enzyme inducing anticonvulsants are not eligible.\n   * Medications that prolong QTc: Patients who require treatment with medications known to prolong QTc are not eligible","10 Years",{"count":53,"type":21},41,[55],"PHASE1","This study is a Phase 1\u002F1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.",[58],"Osteosarcoma",[60,61,62,63,64,65,66],"Pediatrics","Adults","Phase 1","Losartan","Sunitinib","Maximum Tolerated Dose","Recommended Phase 2 Dose","RECRUITING","2026-08-13",{"date":70,"type":36},"2026-08-17",{"date":72,"type":36},"2019-08-26",{"date":74,"type":21},"2029-08-01",{"name":42,"class":43},4,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100651421","novel-couple-based-mindfulness-intervention-for-metastatic-colorectal-cancer-100651421","NCT07759921","Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer","Feasibility and Acceptability of a Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Provision to sign and date the consent form.\n* Stated willingness to comply with all study procedures and be available for the duration of the study.\n* Be aged \\> 18 years to 85.\n* Fluent in English language. All study materials, including the informed consent form, participant workbooks, and questionnaires, are currently available only in English. Participation requires the ability to independently read and engage with written study materials (including the participant workbook), which are integral to the intervention session content and home practices. Therefore, individuals who are unable to read study materials in English are not eligible to participate. At this time, the intervention has not been translated or validated in other languages, therefore participation is limited to individuals who can read, speak, and understand English to ensure that participants are able to fully engage with study activities.\n* Be a person (i.e., patient) diagnosed with metastatic colorectal cancer (mCRC) or a partner (e.g., spouse) of someone diagnosed with mCRC.\n* Indicates a score \\>0 on the Distress Thermometer\n* Has access to computer\u002Finternet through with video-conferencing (phone, laptop, tablet, desktop computer)\n\nAdditional eligibility criteria include:\n\nAdditional patient participant inclusion criteria:\n\n* Has a current diagnosis of metastatic (Stage IV, recurrent) colorectal cancer\n* Has an ECOG status \\\u003C2 or otherwise deemed appropriate for study participation by a clinician\n* Is in a committed relationship with a romantic partner for \\>6 months. Monogamy is not required for eligibility; however, in cases of polyamorous relationships, the patient will designate a primary partner for participation in the study.\n\nAdditional partner participant inclusion criteria:\n\n• Has been in a committed relationship \\>6 months with a patient who meets the above eligibility criteria\n\nEligibility for relationship status will be self-reported by participants during recruitment.\n\nExclusion Criteria:\n\n* One or both members of the couple has an active or poorly controlled serious mental illness (e.g., psychotic disorder), cognitive impairment (e.g., dementia), or medical condition (e.g., significant impaired sight\u002Fhearing) that would compromise participation.\n* The couple is currently in active couples (e.g., marital) therapy together.\n\nParticipants who are physically or mentally too ill to participate or those with major cognitive impairments are excluded because they may not be able to engage with intervention sessions, surveys. No exclusions will be made based on sexual orientation, race, gender, or other sociodemographic features. Because patients with mCRC are living longer, and patients and partners can experience distress at various times since their diagnosis, we do not limit participation by time since diagnosis.",true,"85 Years",{"count":87,"type":21},90,[89],"NA","The overall objective of this study is to learn whether a newly developed couple-based mindfulness program (Mindful PaCT) is practical to complete (feasible), helpful and well-received (acceptable), and relevant for patients with metastatic colorectal cancer (mCRC) and their partners.",[92,93],"Colorectal Cancer","Metastatic Colorectal Cancer (CRC)",[95,96,97],"Couple","Partner","Caregiver","2026-08-12",{"date":100,"type":36},"2026-08-14",{"date":102,"type":21},"2026-12",{"date":104,"type":21},"2030-12",{"name":42,"class":43},1,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":84,"sex":114,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":106},"100457480","phase-4-etonogestrel-implant-as-emergency-contraception-100457480","NCT05237141","Etonogestrel Implant as Emergency Contraception","Etonogestrel Implant as Emergency Contraception: A Pilot Pharmacodynamic Study","Inclusion Criteria:\n\n* BMI less than or equal to 28kg\u002Fm2\n* Intact uterus with at least one ovary\n* Regular menstrual cycles that occur every 21-35 days\n* If patient is postpartum or post-second trimester abortion, 3 menses (2 cycles) must have occurred prior to enrollment\n* If patient had a first trimester abortion or pregnancy loss, she must have one spontaneous menses prior to enrollment\n* Desires insertion of an etonogestrel contraceptive implant for contraception\n* Not currently pregnant or trying to become pregnant\n* Willing to abstain from medications and supplements known to induce\u002Finhibit CYP3A4 during the study\n\nExclusion Criteria:\n\n* Have a known hypersensitivity or contraindications to etonogestrel.\n* Medical conditions that affect liver function (e.g., hepatitis, cirrhosis; assessed via participant self-report)\n* Known or suspected current alcohol dependence syndrome or any illicit drug use that may affect the metabolism of the etonogestrel.\n* Uncontrolled thyroid disorder.\n* Use of long-acting injectable hormonal contraceptive within the past 9 months\n* Current use of hormonal oral, patch, intravaginal, or intrauterine contraception","FEMALE","40 Years",{"count":117,"type":21},12,[119],"PHASE4","The investigators propose a single site, single arm, open label mechanism of action pharmacodynamic pilot study of etonogestrel implant insertion prior to an luteinizing hormone (LH) surge. The investigators will evaluate ovulation rates via serum levels of reproductive hormones and transvaginal ultrasound findings following placement of an etonogestrel implant once the dominant follicle reaches a size of 15mm or greater, but prior to an LH surge, in persons with prior documented regular cycles and confirmed ovulation. The researchers' hypothesis is that ovulation will be inhibited if the etonogestrel implant is placed prior to an LH surge.\n\nBased on data from the Food and Drug Administration label for Nexplanon, etonogestrel rises to levels associated with ovulation suppression within 8 hours of placement. Given this rapid increase, it is therefore plausible to assume that ovulation can be inhibited by the implant if placed prior to an LH surge. This study is novel as there have been no published studies evaluating an etonogestrel implant for this indication.\n\nThe contribution of this proposed research to the literature is significant because current recommendations from the Center for Disease Control (CDC) regarding timing of etonogestrel implant placement are stringent and not patient-centered. Any day insertion of the etonogestrel implant is supported by retrospective data and this pharmacodynamic data would further support the literature for any day insertion without the need for additional emergency contraception. If results support the investigators' hypothesis, it could increase access to contraception and decrease duplicative therapy.",[122],"Contraception","2026-08-10",{"date":125,"type":36},"2026-08-11",{"date":127,"type":36},"2022-04-01",{"date":129,"type":21},"2027-12",{"name":42,"class":43},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":114,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":106},"100436477","eras-in-pediatric--adolescent-gynecology-preoperative-counseling-100436477","NCT04963751","ERAS in Pediatric & Adolescent Gynecology Preoperative Counseling","ERAS in Pediatric and Adolescent Gynecology: How Important is Preoperative Counseling in Patient Outcomes and Does Parent Versus Patient Counseling Impact Success?","Inclusion Criteria:\n\n* 9- 17 years of age\n* Patient is undergoing abdominal surgery and being managed under the ERAS protocol\n\nExclusion Criteria:\n\n* Developmental delay (IQ \\\u003C 70) determined by documentation in medical record\n* Emergency or non-elective surgical cases\n* Patients who attend clinic appointments independently from their caregiver","9 Years","17 Years",{"count":141,"type":21},60,[89],"The Investigator propose a randomized trial that will assess whether participant involvement in pre-operative counseling for ERAS improves post-surgical pain scores. The Investigator will also assess participant compliance to ERAS-prescribed medications, and functionality (return to school). Each participant who is enrolled in the study will be assigned to 1) pre-operative counseling with participant's caregiver or 2) caregiver-only counseling.",[145,146],"Enhanced Recovery After Surgery","Gynecologic Disease",[148,149,60],"Gynecology","ERAS",{"date":125,"type":36},{"date":152,"type":36},"2022-09-08",{"date":154,"type":21},"2028-06-30",{"name":42,"class":43},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":106},"100648241","supporting-medtronic-780g-insulin-pump-adoption-in-latino-patients-a-spanish---language-training-initiative-100648241","NCT07720388","Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative","APOYO780G","Inclusion Criteria:\n\n* Age 10 - 20 years old\n* Diagnosis of type 1 diabetes\n* Self-identify as Latino\u002FHispanic (determined via self-report and\u002For electronic health record)\n* Currently managing diabetes using any regimen, including multiple daily injections (MDI) or any non-Medtronic automated insulin delivery system\n* Willing to transition to and use the Medtronic MiniMed 780G system for the duration of the study\n\nExclusion Criteria:\n\n* Current use of any Medtronic technology\n* More than 1 episode of diabetic ketoacidosis (DKA) within 12 months of study enrollment\n* Current pregnancy (self-reported), due to limited safety data for use of the Medtronic MiniMed 780G system during pregnancy\n* Presence of any significant medical condition that, in the opinion of the investigator, would interfere with study participation or data interpretation\n* Inability or unwillingness to use the Medtronic MiniMed 780G system for the duration of the study","20 Years",{"count":165,"type":21},15,[89],"This study plans to learn more about whether a support program delivered in Spanish or both English and Spanish for bilingual families helps Latino youth with Type 1 Diabetes (T1D) successfully use the Medtronic MiniMed 780G system.\n\nThe main question it aims to answer is:\n\nDoes a linguistically and culturally tailored onboarding model for an automated insulin delivery system close the gap in technology adoption and improve health outcomes?\n\nParticipants will:\n\n* Use the Medtronic MiniMed 780G Automated Insulin Delivery system for eight months\n* Attend one in-person nutrition support and insulin pump start class\n* Participate in regular virtual check-ins with native Spanish-speaking study team members",[169],"Diabetes Mellitus, Type 1 Diabetes","2026-08-06",{"date":125,"type":36},{"date":173,"type":21},"2026-08",{"date":175,"type":21},"2027-03",{"name":42,"class":43},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":106},"100647266","aggressive-lipid-lowering-therapy-in-ici-treated-melanoma-100647266","NCT07704918","Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma","Lipid Lowering Therapy for Atherosclerotic Disease in Melanoma Patients Receiving Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Provision to sign and date the consent form.\n* Stated willingness to comply with all study procedures and be available for the duration of the study.\n* Be a male aged ≥55 years or a female aged ≥65 years.\n* For those able to bear children, documentation of menopausal status via approximate last menstrual period or hysterectomy due to contraindication of pregnancy for the CCTA procedure.\n* Have a melanoma diagnosis without prior ICI use and planning to start on ICI therapy (PD-1, PD-L1, CTLA-4, LAG3) as standard of care for their cancer.\n* Plaque stage ≥ 1 on screening CCTA.\n\nExclusion Criteria:\n\n* Any prior major cardiovascular event, defined as myocardial infarction, stroke, coronary revascularization, or other major cardiovascular event determined to be significant by the principal investigator.\n* Meeting any of the standard CCTA contraindications listed below:\n* Allergy to iodinated contrast or history of contrast-induced nephropathy\n* Renal insufficiency (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation). A current eGFR value (collected\u002Fcalculated within 3 months from screening visit) is required at baseline.\n* Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., \\> 80 beats per minute). EKG must be performed within 1 year of screening visit.\n* Hemodynamic instability\n* Weight \\> 400 lbs. (181 kg) or above manufacturer-recommended limit for scanner and table, whichever is lower\n* Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment\n* Pregnancy\n* Inability to hold breath for \\> 10 seconds\n* Contraindication to dosing with beta blocker as needed or nitroglycerin prior to CCTA procedure\n* Inability to cooperate with scan acquisition and\u002For breath-hold instructions\n* Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA\n* If a patient's fast LDL-C is \\> 190 mg\u002FdL, this is consistent with underlying familial hypercholesterolemia, and they will not be eligible for the study.\n* If a patient's CCTA demonstrates previously undiagnosed obstructive coronary disease, they will not be eligible for the study. Obstructive disease will be defined as \\>50% obstruction in the left main coronary artery, or \\>70% obstruction elsewhere in the coronary tree.","55 Years",{"count":186,"type":21},40,[89],"Immune checkpoint inhibitors (ICIs) are a class of medications that are now standard in the treatment of melanoma. These are standard therapy for melanoma, but long-term side effects on disease in the heart arteries is poorly understood. In this study, melanoma patients receiving ICIs for the first time will undergo a coronary computed tomography angiography (CCTA) scan. CCTA results will be analyzed by the FDA-approved Cleerly TM image analysis pipeline. Patients with disease in their heart arteries will be randomized to usual care or aggressive lipid lowering therapy. Those in the aggressive lipid lowering therapy arm will be seen by a cardiologist and placed on standard lipid lowering medications with a goal of achieving an LDL-C ≤ 55mg\u002FdL. Follow-up CCTA scans will occur at 12-month and 24-month timepoints. The primary outcome of interest will be differences in LDL-C levels between the two arms at the 12-month timepoint. The secondary outcome of interest will be the differences in total plaque volume between the two arms at the 12-month timepoint.",[190],"Melanoma",[192,193,194],"atherosclerosis","coronary artery disease","coronary atherosclerosis",{"date":196,"type":36},"2026-08-07",{"date":198,"type":21},"2026-12-31",{"date":200,"type":21},"2028-12",{"name":42,"class":43},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":84,"sex":17,"minAge":210,"maxAge":85,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},"100632647","safety-and-tolerability-trial-of-psilocybin-in-healthy-older-adults-100632647","NCT07516405","Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","Psil-Pk","Inclusion Criteria:\n\n* Aged 65-85 years \\& be male, female, or non-binary\n* Generally healthy\n* Have an identified support person\n* Capacity to Consent\n\nExclusion Criteria:\n\n* Unstable medical condition\n* Risk for hypertensive crisis (screening blood pressure \\>140\u002F90 mmHg)\n* Significant central nervous system (CNS) pathology\n* Primary psychotic or affective psychotic disorders\n* Family history of psychotic or serious bipolar spectrum illnesses\n* High risk of adverse emotional or behavioral reaction\n* Active substance use disorders (SUDs)\n* Extensive use of serotonergic hallucinogens\n* High risk of completed suicide\n* History of hallucinogen persisting perception disorder (HPPD)\n* Concurrent Medications: centrally-acting serotonergic agents; antipsychotics; certain mood stabilizers, aldehyde dehydrogenase inhibitors; significant inhibitors of UGT 1A9 or UGT 1A10\n* Certain psychiatric conditions\n* Presence of relevant finding (psychological, physical symptom, medication) prior to dosing that would make a participant unsuitable for the study","65 Years",{"count":186,"type":21},[55],"This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.",[215,216],"Healthy Volunteer","Older Adults (65-85 Years)",[218,219,220],"healthy older adults ages 65-85","psilocybin safety","psilocybin tolerability",{"date":123,"type":36},{"date":223,"type":36},"2026-04-01",{"date":225,"type":21},"2028-03",{"name":42,"class":43},6,{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":236,"maxAge":139,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":255,"locationsCount":106},"100632436","headache-education-and-awareness-vs-daily-mindfulness-strategies---understanding-pain-100632436","NCT07513662","Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding Pain","Feasibility Trial of a Remotely-Delivered Mindfulness-Based Intervention for Adolescents With Migraine","HEADS-UP","Inclusion Criteria:\n\n* Age 12 to 17 years old\n* Diagnosed with migraine by medical provider using criteria from the International Classification of Headache Disorders, Third Edition\n* Patient report of at least 6 headache days per month\n* At least mild headache-related disability, as assessed by PedMIDAS score \\> 10\n* Stable dose (≥4 weeks) of prophylactic migraine medication or no current prophylactic medication at enrollment\n* Adolescent participant fluent in English for the intervention content\n\nExclusion Criteria:\n\n* Currently engaged in, or previously received 4 or more sessions of behavioral interventions for pain management (e.g., mindfulness or cognitive-behavioral therapy) in the past 6 months\n* Current psychiatric crisis (e.g., active suicidal ideation)\n* Cognitive impairments or developmental delays that interfere with their ability to participate in the study\n* Inability to provide consent\u002Fassent","12 Years",{"count":238,"type":21},72,[89],"The goal of this study (supported by and included in the NIH HEAL Initiative: https:\u002F\u002Fheal.nih.gov\u002F) is to learn if a fully virtual study comparing two telehealth group interventions for adolescents with migraine is feasible and acceptable:\n\n1. Telehealth group mindfulness-based intervention\n2. Telehealth group headache education",[242,243],"Migraine","Migraine in Adolescence",[245,246,247,242,248,249,250],"Adolescent","Mindfulness","Mindfulness Intervention","Headache","Headache Education","Randomized controlled trial",{"date":123,"type":36},{"date":253,"type":21},"2026-10",{"date":200,"type":21},{"name":42,"class":43},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":270,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":106},"100593628","cardioheartconnect-commercially-available-fitness-for-cardiac-rehabilitation-100593628","NCT07008911","CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation","CardioHeartConnect: Commercially Available Fitness mHealth for Cardiac Rehabilitation Among Individuals Recovering From Transcatheter Aortic Valve Replacement","Inclusion Criteria:\n\n* Appropriate for cardiac rehabilitation (CR) referral, as determined by the UCHealth Structural Heart \\& Valve Clinic team\n* Community-dwelling\n* Reside in the United States\n* Able to speak and understand English\n* Able to provide informed consent\n* Able to stand with or without an assistive device\n* Able to see and hear content on the Peloton App via phone, tablet, or computer\n\nExclusion Criteria:\n\n\\- Determined to be inappropriate for cardiac rehabilitation referral by the UCHealth Structural Heart and Valve Clinic team",{"count":264,"type":21},200,[89],"This trial evaluates the effectiveness of CardioHeartConnect, an eight-week mobile cardiac rehabilitation intervention using Peloton fitness modules, compared to educational control among patients recovering from transcatheter aortic valve replacement (TAVR). The study aims to improve physical activity, functional capacity, quality of life, and cardiovascular health using wearable devices and a digital engagement platform. A total of 200 patients will be recruited from the UCHealth Structural Heart and Valve Clinic and randomized to either CardioHeartConnect or CardioHeartEd. Participants will be assessed at baseline, 8 weeks, and 12 months using surveys, smartwatch data, and electronic health records.",[268,269],"Aortic Valve Stenosis","Aortic Valve Disease",[271,272,273,274,275],"Cardiac Rehabilitation","Transcatheter Aortic Valve Replacement","TAVR","Mobile Health","Peloton","2026-07-31",{"date":278,"type":36},"2026-08-03",{"date":280,"type":36},"2025-08-29",{"date":74,"type":21},{"name":42,"class":43},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":290,"maxAge":236,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":300,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":106},"100614574","pilot-trial-of-an-emotion-regulation-and-executive-functioning-intervention-for-self-injurious-thoughts-and-behaviors-sitbs-in-children-100614574","NCT07281365","Pilot Trial of an Emotion Regulation and Executive Functioning Intervention for Self-Injurious Thoughts and Behaviors (SITBs) in Children","Proof-of-Concept Trial of an Emotion Regulation and Executive Functioning Intervention for SITBs in Children","Inclusion Criteria:\n\n* between the ages of 7-12\n* at least one caregiver\u002Flegal guardian able to participate (more permitted)\n* experienced at least one episode of SITBs within the last month\n* ability to attend weekly sessions in-person or via telehealth\n* ability to attend baseline and post-treatment assessments in-person.\n* estimated verbal IQ of 70 or greater\n\nExclusion Criteria\n\n* symptoms interfering with ability to participate in assessments\u002Ftherapy (i.e., psychosis)\n* estimated verbal IQ\\\u003C70 or previous diagnosis of intellectual development disorder\n* requiring inpatient psychiatric stabilization or high-intensity intervention to prevent hospitalization\n* active substance use\n* ward of the state","7 Years",{"count":292,"type":21},52,[89],"The goal of this study is to develop and test an outpatient intervention for preadolescents (ages 7-12) with self-injurious thoughts and behaviors (SITBs).\n\nThe main questions it aims to answer are:\n\n1. Are the recruitment targets and study design feasible?\n2. Is the new intervention feasible, acceptable, and appropriate?\n3. Does the new intervention lead to more improvements in SITBs, mental health symptoms, and treatment targets relative to treatment as usual (TAU)?\n\nIn Phase 1 (pre-implementation, months 1-6), enrolled preadolescent and caregiver dyads will receive TAU. In Phase 2 (post-implementation, months 7-13), enrolled dyads will receive the newly-developed SITB intervention. Participants will be recruited through referrals from the psychiatric emergency department at Children's Hospital Colorado. Participants will:\n\n1. Complete an initial baseline assessment to determine eligibility and assess SITBs, mental health symptoms, executive functioning, and emotion regulation\n2. Participate in an intervention lasting 6-12 weeks, including weekly or biweekly sessions\n3. Complete additional assessments at post-treatment and 3-month follow-up\n4. Participate in an interview sharing their perceptions of the intervention",[296,297,298,299],"Self-injury","Suicidal Ideation and Behavior","Executive Functioning","Emotion Regulation",[301,302,303,304,305,306],"Preadolescents","Children","Self-Injury","Suicidal ideation and behavior","Feasibility","Pilot Trial","2026-07-27",{"date":309,"type":36},"2026-07-29",{"date":102,"type":21},{"date":312,"type":21},"2028-05",{"name":42,"class":43},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":4},"100648892","reminder-enhanced-incentive-spirometry-evaluation-100648892","NCT07728214","Reminder-enhanced Incentive Spirometry Evaluation","Reminder-enhanced Incentive Spirometry Evaluation (RISE)","RISE","Inclusion Criteria:\n\n* ≥18 years\n* Planned non-cardiac surgery under general anesthesia with at least one night of hospitalization expected\n* Preoperative ARISCAT risk score ≥26\n* Signed informed consent\n\nExclusion Criteria:\n\n* Inability to perform IS due to refusal, cognitive impairment, neuromuscular weakness, anatomical, or any other reasons (e.g., tracheotomy, oral surgery, unable to hold incentive spirometer)\n* Have a severe hearing or visual acuity impairment that prevents them from hearing or seeing the audible and visual IS reminders\n* Are part of a vulnerable population (minors, pregnant, prisoners)\n* Lack of informed consent",{"count":323,"type":21},88,[89],"The purpose of this study is to test whether automatic reminders with a light and a soft sound help patients improve deep breathing exercises after surgery. These breathing exercises are routinely done with the help of a plastic device that you attach to your mouth and you take a deep breath. These exercises are routinely recommended after major surgery to improve the oxygen level in your blood and reduce other respiratory problems.",[327],"Hypoxemia",[329,330,331,332,333,334,327,335],"Incentive Spirometry","IS","Spirometer","InSee Device","Postoperative Pulmonary Complications","Hypoxia","Breathing Exercises","2026-07-22",{"date":307,"type":36},{"date":339,"type":21},"2026-11-01",{"date":341,"type":21},"2029-01-01",{"name":42,"class":43},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":114,"minAge":18,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":365},"100581914","phase-1-cirtuvivintolaparib-in-breast-cancer-susceptibility-genehomologous-recombination-deficiency-platinum-resistant-ovarian-cancer-100581914","NCT06856499","Cirtuvivint\u002FOlaparib in Breast Cancer Susceptibility Gene\u002FHomologous Recombination Deficiency Platinum Resistant Ovarian Cancer","Phase I Evaluation of Combination CLK\u002FDYRK (Cirtuvivint) Inhibition With PARP Inhibition (Olaparib) in BRCA\u002FHRD Platinum Resistant Ovarian Cancer","Inclusion Criteria:\n\n1. Provision to sign and date the consent form.\n2. Stated willingness to comply with all study procedures and be available for the duration of the study.\n3. Woman aged ≥18 years of age\n4. Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 1 or 2\n5. Patients must have a confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer\n6. Patients must have platinum-resistant disease defined as radiographic progression less than 6 months from last dose of most recent platinum therapy\n7. Patients must have measurable disease by defined RECIST 1.1 criteria\n8. Prior anticancer therapy:\n\n   * Patients must have received at least one prior platinum-based chemotherapy regimen\n   * Patients may not have received more than 3 prior lines of systemic therapy\n   * Neoadjuvant +\u002F- adjuvant therapies are considered 1 line of therapy\n   * Maintenance therapy (eg, Bevacizumab, PARP inhibitors) will be considered part of preceding line of therapy (ie, not counted independently)\n   * Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)\n   * Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance\n   * Prior radiation is allowed and is not considered a line of treatment\n9. Patients must have had testing for BRCA mutation (tumor or germline) and tumor HRD testing, and have been positive for one and\u002For the other.\n10. Patients must have received a prior PARP inhibitor as either treatment or maintenance therapy\n11. Patients must have adequate hematologic, liver, and kidney function as defined as:\n\n    * Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL (1500\u002FµL)\n    * Platelet count ≥ 100 x 109\u002FL (100,000 µL)\n    * Hemoglobin ≥ 10.0 g\u002FdL with no blood transfusion in the past 28 days\n    * Serum creatinine ≤ 1.5 x upper limit of normal (ULN)\n    * Patients must have creatinine clearance estimated of ≥51 mL\u002Fmin using the Cockcroft-Gault equation or based on a 24 hour urine test\n    * Aspartate aminotransferase (AST)(Serum Glutamic Oxaloacetic Transaminase (SGOT)) and alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x ULN unless liver metastases are present in which case they must be ≤ 5x ULN\n    * Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \\\u003C 3.0 x ULN)\n    * Serum albumin ≥ 2 g\u002FdL\n12. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n13. Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and\u002For family member available will also be eligible.\n\nExclusion Criteria:\n\n1. Patients with clear cell, mucinous, sarcomatous, low grade\u002Fborderline, germ cell, or sex-cord stromal type ovarian tumor\n2. Patients with platinum refractory disease as defined by those who have progressed during or within 4 weeks of receiving platinum-based therapy\n3. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment\n4. Patients with myelodysplastic syndrome\u002Facute myeloid leukemia or with features suggestive of myelodysplastic syndrome\u002Facute myeloid leukemia.\n5. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to:\n\n   * Uncontrolled major seizure disorder\n   * Unstable spinal cord compression\n   * Any psychiatric disorder that prohibits obtaining informed consent.\n   * Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of therapy\n6. Patients with clinically significant cardiac disease including, but not limited to, any of the following\n\n   * Myocardial infarction ≤ 6 months prior to first dose\n   * Uncontrolled ventricular arrhythmia, recent (within 3 months)\n   * Superior vena cava syndrome\n   * Unstable angina pectoris\n   * Uncontrolled congestive heart failure (New York Heart Association \\> class II)\n   * Uncontrolled ≥ Grade 3 hypertension (per CTCAE)\n   * Uncontrolled cardiac arrhythmias\n7. Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment\n8. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)\n9. Persistent toxicities (\\>\u002F= Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia or peripheral sensory neuropathy\n10. Patients with duodenal stent or other GI disorder\u002Fdefect that would interfere with absorption of oral medication\n\n    o Includes patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication\n11. Patients with known untreated or symptomatic central nervous system (CNS) metastases\n12. Prior known hypersensitivity reaction to study drugs and\u002For any of their excipients\n13. Minor or major surgical procedure within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\n14. Inability to comply with study and follow-up procedures\n15. Patients deemed otherwise clinically unfit for clinical trial per investigators discretion.",{"count":351,"type":21},50,[55],"The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy.\n\nIf a participant is a good fit for the study, and they enroll in the study, they will:\n\n* Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days.\n* Take the study medications, Cirtuvivint and Olaparib. Participants will take Olaparib every day. Participants will either take Cirtuvivint 5 days per week or 2 days per week.",[355,356,357],"Endometrioid Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer",{"date":359,"type":36},"2026-07-24",{"date":361,"type":36},"2025-12-08",{"date":363,"type":21},"2030-09-01",{"name":42,"class":43},2,{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":377,"briefSummary":378,"conditions":379,"keywords":382,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":387,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":365},"100578386","navigate-kidney-a-multi-level-intervention-to-reduce-kidney-health-disparities-100578386","NCT06810622","NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities","Navigate Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities Among Individuals With Kidney Disease","NAV-Kidney","Inclusion Criteria:\n\n* Adults ≥ 18 years of age,\n* Adults who are not pregnant,\n* Adults who are not incarcerated,\n* Adults who have advanced kidney disease with an eGFR of 15-29 mL\u002Fmin\u002F1.73m2). No other measures are used to identify eligible patients.\n\nExclusion Criteria:\n\n* Previous kidney transplant\n* Previous surgery for dialysis such as an arteriovenous fistula, arteriovenous graft, or peritoneal dialysis catheter placement\n* On chronic dialysis\n* Conservative management or primary goal is palliation\n* Incarcerated\n* Pregnant\\*\n* Under 18 years of age\n* Moderate to severe dementia\n* Deaf persons\n* Lacking health insurance\\*\\*\n* Investigator Discretion: Individuals who, in the judgment of the Site PI (or designee), are deemed unsuitable for participation due to behavioral or logistical circumstances that could compromise study integrity or the safety of the participant or staff.","75 Years",{"count":376,"type":21},448,[89],"The overarching goal of this project is to refine and adapt previous work on the NAVIGATE-Kidney project for individuals with CKD. The investigators hypothesize that the multilevel NAVIGATE-Kidney program intervention will reduce the rate of central venous catheter use at KRT start (primary outcome), increase the rate of optimal KRT starts (secondary outcome), increase patient activation, and reduce decisional conflict (patient-centered outcomes) for individuals with advanced CKD. The project will have four (4) aims.",[380,381],"Kidney Diseases","Chronic Kidney Diseases",[383,384,385,386],"Kidney","Chronic","Dialysis","Transplant",{"date":359,"type":36},{"date":389,"type":36},"2026-03-18",{"date":391,"type":21},"2029-05-15",{"name":42,"class":43},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":84,"sex":114,"minAge":18,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":411,"locationsCount":106},"100648632","development-of-an-alcohol-cannabis-and-sexual-assault-risk-reduction-program-for-high-risk-college-women-100648632","NCT07726004","Development of an Alcohol, Cannabis, and Sexual Assault Risk Reduction Program for High Risk College Women","Development of an Alcohol, Cannabis, and Sexual Assault Risk Reduction Program for High Risk College Women, Pilot RCT","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study determined at pre-screening\n3. Between the ages of 18-24 years old determined at pre-screening\n4. Identifies as a woman determined at pre-screening\n5. Is currently enrolled as an undergraduate in Colorado with a valid student email address determined at pre-screening\n6. Engaged in heavy episodic drinking (i.e., 4+ drinks within a two-hour period) at least once in the past month with an intention to drink in the future determined at pre-screening\n7. Engaged in using cannabis at least once in the past month with an intention to use in the future determined at pre-screening\n8. Is available to attend sessions on specific dates\n9. Has a phone they can complete web-based surveys on determined at pre-screening\n\nExclusion Criteria:\n\n1\\. There are no exclusion criteria aside from not meeting inclusion criteria.","24 Years",{"count":264,"type":21},[89],"The goal of this clinical trial is to assess the feasibility of the Enhanced Assess, Acknowledge, and Act Sexual Assault Resistance Program with alcohol and cannabis content (EAAA+) in undergraduate college women between ages 18-24 years old who use alcohol and cannabis. The main objectives it aims to answer are:\n\n* To determine the feasibility of a randomized controlled trial comparing EAAA+ to an assessment only control condition.\n* To determine if EAAA+ will result in larger decreases in HED and cannabis use, more accurate perceptions of alcohol and cannabis norms, and greater increases in PBS at follow up.\n* To determine if EAAA+ will result in (1) greater increases in SA risk perception and use of assertive SA resistance strategies and (2) decreased barriers to SA resistance while using alcohol and cannabis, and (3) greater reductions in incapacitated SA.\n\nResearchers will compare participants who received EAAA+ to an assessment only condition to test the objectives stated above.\n\nParticipants will:\n\n* Sign an informed consent form and complete a survey. Once the survey is completed, they will be randomly assigned to complete the sexual assault education program or not.\n* Participants assigned to the sexual assault education program will complete two in-person sessions (about 7 hours each) or four in-person sessions (about 3.5 hours each) and will also complete an online module in between modules 2 and 3 as part of the education program and complete four short surveys.\n* Complete 4 weeks of assessments and complete a follow-up survey at 1, 3, and 6 months after the initial session.",[405],"Enhanced Assess, Acknowledge, and Act Sexual Assault Resistance Program With Alcohol and Cannabis Content","2026-07-21",{"date":359,"type":36},{"date":173,"type":21},{"date":410,"type":21},"2027-02",{"name":42,"class":43},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":422,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":106},"100595886","early-phase-1-5-aminolevulinic-acid-aided-resection-margins-in-sarcoma-100595886","NCT07038278","5-AminoLevulinic Acid Aided Resection Margins in Sarcoma","5-AminoLevulinic Acid Aided Resection Margins in Sarcoma (5-ALARMS)","5-ALARMS","Inclusion Criteria:\n\n1. Histological confirmation of any subtype of primary Grades 2 or 3 soft tissue sarcomas (STS), per biopsy evaluation by a pathologist, according to Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).\n2. Treatment decision includes planned surgical resection of STS.\n3. Age ≥18 years at time of consent.\n4. ECOG Performance Status 0 - 1.\n5. Hematology and blood chemistry parameters defined by:\n\n   1. Leukocytes ≥ 3 × 10(9)\u002FL\n   2. Absolute neutrophil count ≥ 1.5 × 10(9)\u002FL\n   3. Platelets ≥ 100 × 109\u002FL, transfusions may be used to raise platelets to ≥ 100 × 10(9)\u002FL (no washout required)\n   4. Hemoglobin ≥ 9 g\u002FdL, transfusions may be used to raise Hgb to ≥ 9 g\u002FdL (no washout required)\n   5. Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)\n   6. Aspartate transaminase (AST) \u002F alanine transaminase (ALT) ≤ 2.5 × institutional ULN\n   7. Creatinine within normal institutional limits OR creatinine clearance ≥ 30 mL\u002Fmin\u002F1.73 m2 for patients with creatinine above institutional ULN\n6. Participants of reproductive potential must agree to using adequate contraception (e.g., hormonal or barrier method of birth control; abstinence, an intrauterine device) for the duration of study participation (including dosing interruptions) and up to 42 days after end of study intervention; or be surgically sterilized (e.g., hysterectomy, tubal ligation, or vasectomy).\n7. Ability to swallow study agent.\n8. Ability to understand and willingness to sign an informed consent form.\n9. Ability and stated willingness to adhere to the study visit schedule and other protocol procedures\u002Frequirements for the duration of the study.\n\nInclusion of Minorities and Other Underrepresented Populations Recruitment is open and encouraged to all genders, all minorities, and underrepresented populations. Although distributions may vary by disease type, our recruitment procedures have been developed to enroll participants who are representative of the respective target population.\n\nExclusion Criteria:\n\n1. Acute\u002Fchronic forms of porphyria.\n2. Uncontrolled, known concurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness.\n3. Patient has had chemotherapy, tumor resection, or radiation treatment ≤ 21 days prior to surgery.\n4. Simultaneous participation in another clinical trial ≤ 21 days of enrollment or during the duration of the study period.\n5. Planned use of other potentially phototoxic substances (e.g., St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, quinolones and tetracyclines), and topical preparations containing aminolevulinic acid (5-ALA) for 24 hours during the perioperative period (defined as 24 hours prior to surgery to up to 24 hours post-surgery).\n6. Pregnant or planning to become pregnant during study participation or breastfeeding.\n7. Any condition that is in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial.",{"count":421,"type":21},20,[423],"EARLY_PHASE1","The goal of this study is to learn if the intervention using a fluorescent agent 5-Aminolevulinic acid (5-ALA) to aid in the surgical approach to visualize the soft-tissue sarcoma (STS) during surgical resection. 5-ALA goes through the blood stream and into the tumor tissue allowing it to light up when the surgeon uses a special light in the operating room. The technique is called 5-ALA fluorescence-guided surgery (FGS). The main question aims to answer if 5-ALA provide intraoperative fluorescent visualization of soft-tissue sarcoma versus surrounding tissue and demonstrate the efficacy of tumor and surgical margin resections by a gross and histological analysis of fluorescing and non-fluorescing samples immediately after removal. Participants will be asked to orally administer 5-ALA three to four hours prior to surgery in preoperative area.",[426],"Soft Tissue Sarcoma (STS)",[428,429],"soft tissue sarcoma","fluorescence",{"date":336,"type":36},{"date":432,"type":21},"2026-09-01",{"date":434,"type":21},"2028-11-01",{"name":42,"class":43},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":84,"sex":114,"minAge":4,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":444,"phases":4,"briefSummary":445,"conditions":446,"keywords":449,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":106},"100648360","effects-of-glp-1-ras-on-human-lactation-outcomes-100648360","NCT07720414","Effects of GLP-1 RAs on Human Lactation Outcomes","Inclusion Criteria:\n\n* Breastfeeding mothers of single or multiple infants.\n* Milk removal at least 4x daily\n* Eligible for a GLP-1 RA administered subcutaneously (oral GLP-1 RAs contain absorption enhancers, which may drive accumulation in milk)\n* Access to a breastpump, if needed for maintaining breastfeeding behaviors.\n* Willingness to provide 1-3 oz of breastmilk per study visit.\n* Willingness to track and report body weight daily.\n* Willingness to maintain breastfeeding behaviors for the duration of the study.\n\nExclusion Criteria:\n\n* Currently taking GLP-1 RA medication or other weight loss medication\n* Induced lactation, due to unknowns regarding the durability of the mammary gland's milk production after exogenous stimulation.",{"count":443,"type":21},18,"OBSERVATIONAL","There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.\n\nThe main questions the study will address are:\n\n* Does GLP-1 RA-induced weight loss increase or decrease breastmilk production?\n* Does GLP-1 RA-induced weight loss affect the nutritional composition of milk, including milk fat content?\n\nResearchers will assess milk production rates before and after mothers begin taking injected GLP-1 RA medications to decrease their body weight. Weight loss will be confirmed with 7-day body weight averages.\n\nParticipants will:\n\n* Weigh themselves and report measurements daily.\n* Participate in 2-3 morning study visits over approx. 2.5-4.5 months (approx. 3-3.5hrs each).\n\nDuring each visit, participants will:\n\n* Use a study provided breastpump to express milk 3 times hourly for measurement of hourly milk production.\n* Provide 1-3 oz of milk for further study.\n* Answer questions about breastfeeding patterns.",[447,448],"Lactation","Weight Loss",[450,451,452,448],"Breastmilk production","Breastmilk composition","GLP-1","2026-07-17",{"date":336,"type":36},{"date":456,"type":21},"2026-07",{"date":458,"type":21},"2028-06",{"name":42,"class":43},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":84,"sex":114,"minAge":466,"maxAge":184,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":468,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":482},"100591029","phase-2-focusing-on-the-menopausal-transition-to-improve-mid-life-womens-health-100591029","NCT06975111","Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","Inclusion Criteria:\n\n* aged 45-55\n* In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18\n* No current use of hormone therapy or hormonal contraception\n* Presence of a uterus and at least one ovary in order to track menstrual patterns\n* Have a smartphone and broadband access adequate to accept telehealth appointments\n\nExclusion Criteria:\n\n* Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth)\n* Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant.\n* Pregnancy or actively trying to get pregnant\n* Inability to adhere to study protocol schedule\n* Untreated alcoholism\n* Un- Diagnosed abnormal uterine bleeding\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a BMI\\> 30 kg\u002Fm2.","45 Years",{"count":264,"type":21},[24,469],"PHASE3","What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.",[472,473,474,475],"Menopause","Menopause Hot Flashes","Menopause Related Conditions","Cardiovascular",{"date":406,"type":36},{"date":478,"type":36},"2026-03-01",{"date":480,"type":21},"2030-10-01",{"name":42,"class":43},3,{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":84,"sex":114,"minAge":18,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":497,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":505,"locationsCount":365},"100568846","phase-2-convergent-mechanisms-underlying-reprometabolic-syndrome-in-women-100568846","NCT06686537","Convergent Mechanisms Underlying Reprometabolic Syndrome in Women","Convergent Mechanisms Underlying Reprometabolic Syndrome in Women and Sheep","Inclusion Criteria:\n\n* Age 18-38\n* Regular menstrual cycles every 25-35 days\n* No use of reproductive hormones within the past 3 months\n* No use of medications interacting with reproductive hormones\n* Agreement to use reliable barrier contraception or to abstain from intercourse for the duration of the study\n* Normal thyroid stimulating hormone, prolactin and lipid profiles\n* No more than 4 hours of moderate to vigorous intensity exercise per week\n* No history of chronic disease impacting reproductive hormones\n* No contraindications to administration of estradiol\n* No history of estrogen dependent cancer\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* Has diabetes\n* Is a smoker\n* History of venous thromboembolism or known thrombophilia","38 Years",{"count":421,"type":21},[24],"Dr. Nanette Santoro proposes to test the specific question that obesity results in abnormal estradiol response at the level of the pituitary and hypothalamus. This will be shown in diminished pituitary sensitivity to gonadorelin releasing hormone with a reduced estradiol induced luteinizing hormone surge in obese women.",[495,496],"Infertility, Female","Obesity",[496,498,499,500],"Infertility","Hypothalamic-pituitary-ovarian axis","pituitary dysfunction",{"date":406,"type":36},{"date":503,"type":36},"2025-02-25",{"date":129,"type":21},{"name":42,"class":43},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":236,"maxAge":400,"enrollmentInfo":514,"targetDuration":4,"studyType":22,"phases":515,"briefSummary":516,"conditions":517,"keywords":523,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":106},"100560330","phase-1-physiologic-response-to-bariatric-surgery-and-the-impact-of-adjunct-semaglutide-in-adolescents-100560330","NCT06575738","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide - in Adolescents (the PRESSURE Trial)","PRESSURE","Observation Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Male or female biological sex, age 12 through 24 years\n* In the preoperative pathway for vertical sleeve gastrectomy\n\nExclusion Criteria:\n\n* Planned Roux-en-Y gastric bypass\n* Hypothalamic obesity\n* Type 2 Diabetes\n* Current use of oral glucocorticoids (i.e. within 10 days of baseline visit)\n* Current use of insulin\n\nIntervention\u002FTreatment Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Status post vertical sleeve gastrectomy\n* Male or female biological sex, age 12 through 24 years\n* Meeting minimum nutrition goals\n* Obesity: age 12-17 years: BMI ≥95th%ile for age\u002Fsex \\| age 18-24 years: BMI ≥ 30kg\u002Fm\\^2\n* If entering the Intervention phase from the Observational phase: ≤22% BMI loss at 6-24 months postop\n* If entering the Intervention phase from the existing patient pool: ≤22% BMI loss at 6-24 months postop\n\nExclusion Criteria:\n\n* Surgically correctable cause of suboptimal postoperative weight loss\n* Known hypersensitivity to any component of semaglutide\n* Personal or family history of medullary thyroid carcinoma\n* Personal history of multiple endocrine neoplasia type 2\n* Hypothalamic Obesity\n* Type 2 Diabetes\n* History of pancreatitis\n* Uncontrolled hypertension\n* Clinically significant arrhythmia or heart disease that could be exacerbated by increased heart rate\n* Malignant neoplasm within the last 5 years\n* Untreated thyroid disorder\n* Tanner Stage 1\n* Baseline alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥ 5x upper limit of normal\n* Baseline Creatinine \\>1.2mg\u002FdL\n* Active treatment for bulimia nervosa\n* Active major psychiatric disorder limiting informed consent\n* Suicidal ideation of type 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)\n* Intentional self-harm within the previous 1 month\n* Severe unmanaged depression, defined by Center for Epidemiological Studies Depression (CESD) score of 26 or greater and by clinical evaluation\n* Recent change to concomitant medications for hypertension, dyslipidemia, depression or anxiety (\\\u003C4 weeks prior to enrollment)\n* Use of oral glucocorticoids (within 10 days of baseline visit)\n* Use of metformin (within 3 months of baseline visit)\n* Use of insulin secretagogues (within 4 half-lives of the medication of baseline visit)\n* Current use of insulin\n* Use of anti-obesity medications (within 4 half-lives of the medication of baseline visit)\n* Current pregnancy\n* For females of reproductive potential: Plan to become pregnant in the next 8 months\n* For females of reproductive potential: Not on contraception (i.e. two forms of birth control for example oral birth control pills and condoms) for at least 1 month prior to enrollment and agreement to use these during study participation and for an additional 8 weeks after the final dose of study medication",{"count":186,"type":21},[55],"The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide or tirzepatide) can help people 12 to 24 years old who, between 6 and 24 months after bariatric surgery, have not lost as much weight as expected.",[496,518,519,520,521,522],"Adolescent Obesity","Body-Weight Trajectory","Weight Loss Trajectory","Bariatric Surgery","Anti-obesity Agents",[496,524,521,525,526,527],"Anti-obesity medication","Bariatric Surgery Post Operative Outcomes","Semaglutide","Sleeve gastrectomy","2026-07-13",{"date":530,"type":36},"2026-07-15",{"date":532,"type":36},"2024-10-11",{"date":534,"type":21},"2027-10-01",{"name":42,"class":43},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":544,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":548,"conditions":549,"keywords":553,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":106},"100517647","parent-management-training-to-treat-irritability-100517647","NCT06020261","Parent Management Training to Treat Irritability","The Efficacy of Parent Management Training to Treat Irritability","PMT","Inclusion Criteria:\n\n* clinically significant irritability (Clinician Affective Reactivity Index 30 or greater)\n* parent or guardian with whom the child resides for at least 50% of the time is willing to participate in treatment with the child\n\nExclusion Criteria:\n\n* psychiatric instability (danger to self\u002Fothers, risky substance abuse)\n* current active Post-Traumatic Stress Disorder (PTSD) or a severe active stressor (e.g. child abuse)\n* history of severe psychopathology with an established alternate treatment (e.g. autism spectrum disorder, bipolar disorder, schizophrenia, intellectual disability)\n* general medical condition that may be driving irritability or prevent generalizable physiologic measures.\n* screen positive for an intellectual disability via Wechsler Abbreviated Scale of Intelligence Second Edition (WASI II) estimated Intelligence Quotient (IQ)\\\u003C70.","14 Years",{"count":546,"type":21},36,[89],"The goal of this clinical trial is to see if 12 sessions of a Parent Management Training program can treat irritability in children aged 10-14 years old. The main question it aims to answer are:\n\n* Can a Parent Management Training for parents reduce anger outbursts and cranky moods in their children?\n* Can Parent Management Training be done in an outpatient clinic and do parents like it?\n\nUp to 24 families can join this study.\n\nParent participants will complete 12 sessions of Parent Management Training for Irritability. Each session will be 45-55 minutes weekly. They will also participate in the assessments of their child before, during and after treatment.\n\nChild participants will do assessments before, during and after the Parent Management Training treatment.",[550,551,552],"Irritable Mood","Temper Tantrum","Anger",[554,555,556,557,558],"irritability","anger","parenting","temper outbursts","Parent Management Training",{"date":530,"type":36},{"date":561,"type":36},"2025-06-12",{"date":563,"type":21},"2027-06-30",{"name":42,"class":43},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":22,"phases":575,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":591},"100556583","implementation-and-interaction-of-clinician-and-patient-facing-tools-aiming-to-intensify-neurohormonal-medicines-for-heart-failure-100556583","NCT06526988","Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure","Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure With Reduced Ejection Fraction: I-I-CAPTAIN-HF","IICAPTAIN-HF","Inclusion Criteria:\n\nClinician:\n\n* Clinician (MD, PA, NP) who practices in cardiology outpatient clinics\n* Regularly sees patients with left ventricular ejection fraction (EF) \\\u003C\u002F=40%, where their panel of patients over the last year included at least 10 patients with heart failure with reduced ejection fraction (HFrEF)\n\nPatient:\n\n* Age \\> 18 years\n* LVEF \\\u003C\u002F=40% on most recent cardiology imaging study\n* Has a new or return clinic visit with an enrolled clinician within the next 7 days\n* Is missing at least one of the four classes of medications and does not have an allergy to that class: (1) beta blockers, (2) angiotensin receptor-neprilysin inhibitor, (3) aldosterone receptor antagonists, (4) sodium-glucose co-transporter\n\nExclusion Criteria:\n\nPatient:\n\n* Has a left ventricular assist device\n* Under evaluation for or listed for transplant (or s\u002Fp transplant)\n* Glomerular filtration rate (GFR) less than 20 or on dialysis\n* On hospice care\n* Preferred language neither English or Spanish",{"count":574,"type":21},2200,[89],"An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF). When used in combination at recommended doses, patients often experience significant improvements in cardiac function, quality of life, and survival.1,2 However, GDMT underuse occurs for the vast majority of patients with HFrEF. Two recent trials demonstrated improved GDMT prescribing during a clinic visit, each using automated delivery of a patient-centered decision support tool to promote a proactive and holistic approach to prescribing: EPIC-HF (NCT03334188) tested a brief video and checklist document sent to patients just prior to a clinic visit encouraging them to work with their clinicians to make at least 1 positive change to their GDMT; PROMPT-HF (NCT05433220) tested tailored electronic health record (EHR) alerts for GDMT intensification delivered to clinicians during clinic visits. The current I-I-CAPTAIN-HF study aims to broadly implement and test the EPIC-HF patient-facing and PROMPT-HF clinician-facing tools for HFrEF medication intensification at 5 health systems around the country through a pragmatic cluster-randomized implementation-effectiveness trial. This will occur through an initial phase of adaptation of the 2 tools at each health system. Once ready, the 2 tools will be tested using a 2x2 randomization at the clinician-level. In parallel, formal assessment of the implementation of EPIC-HF and PROMPT-HF will work to understand the most effective means of intervention design and delivery, as well as adaptations due to contextual factors to optimize use.",[578],"Heart Failure With Reduced Ejection Fraction",[580,581,582,583],"Heart failure","Patient-centered care","Clinical decision support","Guideline-directed medical therapy","2026-07-10",{"date":528,"type":36},{"date":587,"type":36},"2025-03-06",{"date":589,"type":21},"2028-09-01",{"name":42,"class":43},5,{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":598,"minAge":599,"maxAge":600,"enrollmentInfo":601,"targetDuration":4,"studyType":444,"phases":4,"briefSummary":603,"conditions":604,"keywords":606,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":613,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":106},"100458489","the-intersection-of-oncology-care-and-worker-well-being-100458489","NCT05250284","The Intersection of Oncology Care and Worker Well-Being","Inclusion Criteria:\n\n* Males\n* Ages 21 to 70\n* Newly diagnosed with a first primary solid tumor\n* colorectal, lung, and head and neck\n* Currently employed (defined as working 10+ hours per week) with the intention to continue working or return to work\n* Within 2 months of initiating infusion chemotherapy, oral agent, or radiation therapy","MALE","21 Years","70 Years",{"count":602,"type":21},400,"The goals of this study will be a greater understanding of cancer patients' well-being experience through the care\u002Ftreatment continuum. An important aspect of the study is an understanding of work- and treatment-related challenges experienced by low-income men, many of whom will be Latino. At the 12-month observation period, the investigators will learn whether these men work long-term and how work status relates to well-being.",[605],"Solid Tumor",[607,608,609,610,611,612],"Newly Diagnosed Primary Solid Tumor","Men","Employed","Chemotherapy","Oral Agent","Radiation Therapy",{"date":528,"type":36},{"date":615,"type":36},"2022-04-04",{"date":617,"type":21},"2027-08-31",{"name":42,"class":43},{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":84,"sex":17,"minAge":466,"maxAge":374,"enrollmentInfo":626,"targetDuration":4,"studyType":22,"phases":628,"briefSummary":629,"conditions":630,"keywords":631,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":638,"leadSponsor":640,"locationsCount":76},"100636712","increasing-crc-screening-in-community-health-centers-through-mobile-messaging-optimization-100636712","NCT07569250","Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization","CoSMMO","Eligibility Criteria for CHC Patients Cohorts\n\nInclusion Criteria (CHC Patients):\n\n* Adults 45-75 years old\n* Receive care in partner CHCs\n* Are of average risk for colorectal cancer\n* Received a stool-based testing order at their CHC\n* Have a mobile phone and can receive text messages (Aim 1 quantitative cohort only)\n* Fluent in English, Spanish, or another predominant language to be identified by the PI (applicable to patients focus groups cohort only)\n\nExclusion Criteria (CHC Patients):\n\n* Personal or family history of CRC or colorectal polyps\n* History of inflammatory bowel disease\n* Heritable conditions that put them at above average risk for colorectal cancer (e.g., familial adenomatous polyposis)\n\nEligibility Criteria for CHC Staff Cohorts Inclusion Criteria (CHC Staff)\n\n* Adult employees of participating CHCs\n* Job responsibilities include activities related to CRC screening\n\nExclusion Criteria (CHC Staff)\n\n* None",{"count":627,"type":21},7220,[89],"The goal of this interventional study is to create and test a comprehensive and low burden text message program within existing Community Health Centers (CHC) electronic records system to encourage patients to complete at home colorectal cancer (CRC) screening and to make sure they get follow-up care if their results are abnormal.\n\nFirst, the investigators will learn from clinic staff and patients what their needs and preferences are in terms of use of technology. This information will be used to design the text messages program.\n\n* Clinic patients will participate in focus groups\n* Clinic staff will participate in interviews\n\nSecond, the investigators will test a series of different message versions in two batches (experiments):\n\n* Clinic patients with orders for an at-home colorectal cancer screening kit will receive the different message versions.\n* In the first batch, the messages that get the most engagement from patients will be selected to be used in the second experiment.\n* In the second batch, the investigators will test which messages lead to the most colorectal cancer screening completion.\n* This will be rolled-out within the clinics existing electronic record system. The study team will not receive any information that will identify individual patients.\n\nLastly, the investigators will check again with clinic staff to learn how the program performed, and what would be needed to continue using the text message program in the long run.\n\n-Clinic staff will participate in interviews and surveys.",[92],[632,633,634],"colorectal cancer screening","Text messaging","Community Health Centers (CHC)","2026-07-09",{"date":584,"type":36},{"date":102,"type":21},{"date":639,"type":21},"2032-01",{"name":42,"class":43},{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":114,"minAge":18,"maxAge":648,"enrollmentInfo":649,"targetDuration":4,"studyType":22,"phases":651,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":656,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":227},"100507455","phase-2-an-evaluation-of-maintenance-therapy-combination-mirvetuximab-soravtansine-and-olaparib-100507455","NCT05887609","An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib","A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer","Inclusion Criteria:\n\n* Provision to sign and date the consent form\n* Stated willingness to comply with all study procedures and be available for the duration of the study\n* Be a woman aged ≥18 years of age\n* Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Patients must have a confirmed diagnosis of high-grade serous or endometrioid EOC, primary peritoneal cancer, or fallopian tube cancer\n* Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of prior platinum therapy (not inclusive of current\u002Fmost recent platinum therapy)\n* Patients must have had documented complete or partial response, or stable disease, as defined by RECIST 1.1, from last line of platinum therapy\n* Patients must have available archival tissue block or slides to confirm FRalpha positivity\n* Patients' tumor must have FRalpha high or medium expression\n* Prior anticancer therapy:\n\n  * Patients must have received at least one prior platinum-based chemotherapy regimen for platinum sensitive recurrent disease.\n  * Most recent prior chemotherapy regimen must have consisted of at least 4 completed cycles and no more than 8 completed cycles\n  * Most recent prior chemotherapy regimen must have been platinum based\n  * Patients must have had testing for BRCA mutation (tumor or germline) and, if positive, must have received a prior PARP inhibitor as either treatment or maintenance therapy\n  * Neoadjuvant +\u002F- adjuvant therapies are considered 1 line of therapy\n  * Maintenance therapy (eg, Bevacizumab, PARP inhibitors) will be considered part of preceding line of therapy (ie, not counted independently)\n  * Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)\n  * Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance\n  * Prior Bevacizumab use is allowed, but concurrent use with study combination is prohibited.\n  * Cycle 1 Day 1 of trial therapy must be within 8 weeks of last dose of previous chemotherapy.\n* Patients must have adequate hematologic, liver, and kidney function as defined as:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL (1500\u002FµL)\n  * Platelet count ≥ 100 x 109\u002FL (100,000 µL)\n  * Hemoglobin ≥ 10.0 g\u002FdL with no blood transfusion in the past 28 days\n  * Serum creatinine ≤ 1.5 x upper limit of normal (ULN)\n  * Patients must have creatinine clearance estimated of ≥51 mL\u002Fmin using the Cockcroft-Gault equation or based on a 24 hour urine test\n  * Aspartate aminotransferase (AST)(Serum Glutamic Oxaloacetic Transaminase (SGOT)) and alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x ULN unless liver metastases are present in which case they must be ≤ 5x ULN\n  * Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \\\u003C 3.0 x ULN)\n  * Serum albumin ≥ 2 g\u002FdL\n\nExclusion Criteria:\n\n* Patients with clear cell, mucinous, sarcomatous, low grade\u002Fborderline, germ cell, or sex-cord stromal type ovarian tumor\n* Patients who have progressed through most recent chemotherapy regimen. Stable disease (SD) is permissible.\n* Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment\n* Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions require ongoing treatment\u002Fmonitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and\u002For monocular vision\n* Patients with myelodysplastic syndrome\u002Facute myeloid leukemia or with features suggestive of MDS\u002FAML.\n* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to:\n\n  * Uncontrolled major seizure disorder\n  * Unstable spinal cord compression\n  * Any psychiatric disorder that prohibits obtaining informed consent.\n  * Active hepatitis B or C infection (whether or not on active antiviral therapy)\n  * Immunocompromised patients, e.g., patient who are known to be serologically positive for human immunodeficient virus(HIV)\n  * Active cytomegalovirus infection\n  * Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV\n* Patients with a history of multiple sclerosis (MS) or other demyelinating disease and\u002For Lambert-Eaton syndrome (paraneoplastic syndrome)\n* Patients with clinically significant cardiac disease including, but not limited to, any of the following\n\n  * Myocardial infarction ≤ 6 months prior to first dose\n  * Uncontrolled ventricular arrhythmia, recent (within 3 months)\n  * Superior vena cava syndrome\n  * Unstable angina pectoris\n  * Uncontrolled congestive heart failure (New York Heart Association \\> class II)\n  * Uncontrolled ≥ Grade 3 hypertension (per CTCAE)\n  * Uncontrolled cardiac arrhythmias\n* Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment\n* Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)\n* Patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD) or Extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan , including noninfectious pneumonitis\n* Persistent toxicities (\\>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia\n* Patients requiring use of folate-containing supplements (eg, folate deficiency)\n* Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks.\n* Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.\n* Patients with prior hypersensitivity to monoclonal antibodies (mAb)\n* Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).\n* Women who are pregnant or breastfeeding, and who do not agree to use a highly effective contraceptive method(s) while on study drug and for at least 3 months after the last dose of MIRV and at least 6 months after the last dose of Olaparib. Females of childbearing potential must have a negative serum pregnancy test within 72 hours of study entry.\n* Patients who received prior treatment with MIRV or other FRα- targeting agents\n* Patients with duodenal stent or other GI disorder\u002Fdefect that would interfere with absorption of oral medication\n\n  * Includes patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication\n* Patients with known untreated or symptomatic central nervous system (CNS) metastases\n* Patients with a history of other malignancy within 3 years prior to enrollment\n\n  * Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible\n* Prior known hypersensitivity reaction to study drugs and\u002For any of their excipients\n* Minor or major surgical procedure within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\n* Inability to comply with study and follow-up procedures\n* Patients deemed otherwise clinically unfit for clinical trial per investigators discretion","100 Years",{"count":650,"type":21},53,[24],"The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.",[654,655,357],"Ovary Cancer","Peritoneal Cancer",{"date":528,"type":36},{"date":658,"type":36},"2023-10-03",{"date":660,"type":21},"2031-01-31",{"name":42,"class":43},""]